Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus +7 more
wiley +1 more source
Serological and virological characterization of hepatitis B surface antigen-positive patients with or without Helicobacter pylori co-infection at the university of Gondar comprehensive specialized hospital, Northwest Ethiopia. [PDF]
Belayneh M +6 more
europepmc +1 more source
Plasmepsins as Antimalarial Drug Targets—Then, Now, and the Future
ABSTRACT Malaria is a devastating disease caused by Plasmodium parasites. Plasmodium parasites express ten cathepsin D‐like aspartyl proteases, called plasmepsins (PMs). These PMs have diverse roles fulfill diverse functions throughout the parasite's lifecycle, though several exhibit functional redundancies. Among them, PMV, PMIV, and PMX are essential
Brad E. Sleebs
wiley +1 more source
A US-Based Multi-Site Pilot to Screen Hepatitis B Surface Antigen-Positive Patients for Hepatitis D. [PDF]
Li M +13 more
europepmc +1 more source
Vaccination Status and Influencing Factors of Delayed Vaccination in Toddlers Born to Hepatitis B Surface Antigen-Positive Mothers. [PDF]
Gao J +7 more
europepmc +1 more source
Community-Based Double Reflex Screening Reveals Widespread Hepatitis D Viremia Among Hepatitis B Surface Antigen Carriers in Pakistan. [PDF]
Abbas M, Abbas Z, Sharif MY.
europepmc +1 more source
Transcription of hepatitis B surface antigen shifts from cccDNA to integrated HBV DNA during treatment. [PDF]
Taddese M +15 more
europepmc +1 more source
Mindray CL-900i assay: An effective assay for hepatitis B surface antigen screening with superior specificity. [PDF]
Nasrallah GK +16 more
europepmc +1 more source
Trajectories and Decline of Serum Hepatitis B Surface Antigen Predict Outcomes in Patients With Chronic Hepatitis B. [PDF]
Hsu WF +7 more
europepmc +1 more source

